CHF143.7m market cap
CHF0.18 last close
Evolva is a Swiss, high-tech fermentation company. It has a proprietary yeast technology platform, which it uses to create and manufacture high-value speciality molecules for nutritional and consumer products.
Investment summary
Nootkatone US EPA approval in pest control was delayed as the EPA seeks clarification on one study. Evolva has collaborated with the FDA and submitted all responses, hence is now awaiting a decision. The first EverSweet royalty – albeit small – was received in Q418 and further contributions are expected in H219. Evolva’s overall geographical and product footprint continues to expand and the pipeline remains robust. The company’s aim is to reach cash break-even by FY21/23. H119 results demonstrated a solid performance.
Y/E Dec |
Revenue (CHFm) |
EBITDA (CHFm) |
PBT (CHFm) |
EPS (CHFc) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 6.8 | (37.6) | (40.9) | (7.0) | N/A | N/A |
| 2018A | 8.9 | (23.4) | (25.4) | (3.0) | N/A | N/A |
| 2019E | 10.9 | (15.1) | (15.8) | (2.1) | N/A | N/A |
| 2020E | 18.2 | (10.0) | (10.4) | (1.4) | N/A | N/A |
Industry outlook
Food and health ingredients continue to be in the sweet spot as consumers demand healthier products with cleaner labels without compromising on taste or convenience. Evolva’s fermentation platform aims to deliver these benefits while reducing production costs.
Last updated on 21/11/2019
Sector |
|---|
| Consumer |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (CHFm) | 32.1 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Gerard Hoetmer | Chairman |
| Oliver Walker | CEO |
